title: Renal cell carcinoma in patients with a solitary kidney after nephrectomy treated with radiofrequency ablation: mid term results.
abstract: This retrospective study aimed to evaluate the feasibility and effectiveness of radiofrequency ablation (RFA) in patients with solitary kidney for the treatment of renal cell carcinoma (RCC). Within 2 years 10 patients (seven males, three females; age 65+/-8 years) were treated. All patients had a history of nephrectomy of the contralateral kidney. The indications for RFA were inoperability or high probability of complete renal failure after surgical enucleation of the tumor. 13 tumors with a size between 1.9 and 4.2 cm (average 2.7 cm) were treated. In patients with a tumor diameter larger than 2.5 cm a transarterial embolization was performed prior to RFA to reduce heat sink effect and risk of bleeding. Therapeutical success was defined as a lack of contrast enhancement in follow up examinations and shrinking of the treated area. Furthermore all patients' renal function was monitored. RFA of renal tumors under CT-fluoroscopy was feasible in all patients. Within the follow up (3 and 24 months) no tumor recurrence or major complication was detected. One patient developed another RCC and was successfully treated with a second RF-ablation. None of the patients developed renal failure with the need of hemodialysis. In one of the patients a hemorrhage into the surrounding tissue was noticed, which stopped spontaneously. RFA is a valuable and effective therapeutical option in patients with solitary kidney suffering from inoperable renal cell carcinoma. The complication rate is small and an excellent tumor control can be achieved without deterioration of the renal function.
authors.affiliation: Institute of Clinical Radiology, Ludwig Maximilians-University, Marchioninistrasse, Munich, Germany. ralf-thorsten.hoffmann@med.uni-muenchen.de
authors.forename: Ralf-Thorsten
authors.initials: RT
authors.lastname: Hoffmann
authors.forename: Tobias F
authors.initials: TF
authors.lastname: Jakobs
authors.forename: Constanze H
authors.initials: CH
authors.lastname: Kubisch
authors.forename: Christoph
authors.initials: C
authors.lastname: Trumm
authors.forename: Christof
authors.initials: C
authors.lastname: Weber
authors.forename: Michael
authors.initials: M
authors.lastname: Siebels
authors.forename: Thomas K
authors.initials: TK
authors.lastname: Helmberger
authors.forename: Maximilian F
authors.initials: MF
authors.lastname: Reiser
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D003287:Contrast Media; D004621:Embolization, Therapeutic; D005260:Female; D005471:Fluoroscopy; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local; D009392:Nephrectomy; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media